KR101790286B9 - -2-[2-3--3-]-3'- An oral pharmaceutical composition comprising -2-[2-3-carboxypropionyloxy-3-dimethylaminopropoxy]-3'-methoxybibenzyl or a pharmaceutically acceptable salt thereof - Google Patents

-2-[2-3--3-]-3'- An oral pharmaceutical composition comprising -2-[2-3-carboxypropionyloxy-3-dimethylaminopropoxy]-3'-methoxybibenzyl or a pharmaceutically acceptable salt thereof

Info

Publication number
KR101790286B9
KR101790286B9 KR1020160029881A KR20160029881A KR101790286B9 KR 101790286 B9 KR101790286 B9 KR 101790286B9 KR 1020160029881 A KR1020160029881 A KR 1020160029881A KR 20160029881 A KR20160029881 A KR 20160029881A KR 101790286 B9 KR101790286 B9 KR 101790286B9
Authority
KR
South Korea
Prior art keywords
methoxybibenzyl
carboxypropionyloxy
dimethylaminopropoxy
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
KR1020160029881A
Other languages
Korean (ko)
Other versions
KR20170106126A (en
KR101790286B1 (en
Inventor
최연웅
하대철
권인호
김아영
송희용
정래훈
최보람
Original Assignee
한국유나이티드제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59789653&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101790286(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 한국유나이티드제약 주식회사 filed Critical 한국유나이티드제약 주식회사
Priority to KR1020160029881A priority Critical patent/KR101790286B1/en
Priority to PCT/KR2017/002614 priority patent/WO2017155350A1/en
Priority to JP2018547975A priority patent/JP7366542B2/en
Priority to CN201780028153.9A priority patent/CN109069435B/en
Publication of KR20170106126A publication Critical patent/KR20170106126A/en
Application granted granted Critical
Publication of KR101790286B1 publication Critical patent/KR101790286B1/en
Publication of KR101790286B9 publication Critical patent/KR101790286B9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
KR1020160029881A 2016-03-11 2016-03-11 An oral pharmaceutical composition comprising (±)-2-[2-(3-carboxypropionyloxy)-3-dimethylaminopropoxy]-3'-methoxybibenzyl or a pharmaceutically acceptable salt thereof KR101790286B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1020160029881A KR101790286B1 (en) 2016-03-11 2016-03-11 An oral pharmaceutical composition comprising (±)-2-[2-(3-carboxypropionyloxy)-3-dimethylaminopropoxy]-3'-methoxybibenzyl or a pharmaceutically acceptable salt thereof
PCT/KR2017/002614 WO2017155350A1 (en) 2016-03-11 2017-03-10 Pharmaceutical composition for oral administration comprising (±)-2-[2-(3-carboxypropionyloxy)-3-dimethylaminopropoxy]-3'-methoxybibenzyl or salts thereof
JP2018547975A JP7366542B2 (en) 2016-03-11 2017-03-10 Oral pharmaceutical composition containing (±)-2-[2-(3-carboxypropionyloxy)-3-dimethylaminopropoxy]-3'-methoxybibenzyl or a salt thereof
CN201780028153.9A CN109069435B (en) 2016-03-11 2017-03-10 Oral pharmaceutical composition comprising sarpogrelate or a salt thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160029881A KR101790286B1 (en) 2016-03-11 2016-03-11 An oral pharmaceutical composition comprising (±)-2-[2-(3-carboxypropionyloxy)-3-dimethylaminopropoxy]-3'-methoxybibenzyl or a pharmaceutically acceptable salt thereof

Publications (3)

Publication Number Publication Date
KR20170106126A KR20170106126A (en) 2017-09-20
KR101790286B1 KR101790286B1 (en) 2017-10-26
KR101790286B9 true KR101790286B9 (en) 2022-01-28

Family

ID=59789653

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160029881A KR101790286B1 (en) 2016-03-11 2016-03-11 An oral pharmaceutical composition comprising (±)-2-[2-(3-carboxypropionyloxy)-3-dimethylaminopropoxy]-3'-methoxybibenzyl or a pharmaceutically acceptable salt thereof

Country Status (4)

Country Link
JP (1) JP7366542B2 (en)
KR (1) KR101790286B1 (en)
CN (1) CN109069435B (en)
WO (1) WO2017155350A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102261748B1 (en) 2019-02-13 2021-06-08 한국바이오켐제약 주식회사 Methods for preparing sarpogrelate hydrochloride and pharmaceutical composition comprising the same
KR20210079216A (en) * 2019-12-19 2021-06-29 (주)셀트리온 Pharmaceutical Formulation comprising Cibenzoline or a salt thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101320802B1 (en) * 2010-02-16 2013-10-23 주식회사 드림파마 Multilayer tablet containing release controlled dosage form of sarpogrelate hydrochloride
KR101265491B1 (en) * 2010-08-30 2013-05-16 주식회사 유유제약 Dissolution rate controlled multilayered tablet for oral administration containing sarpogrelate hydrochloride and manufacturing method thereof
KR20120060983A (en) * 2010-10-04 2012-06-12 근화제약주식회사 Sustained release dosage form and manufacturing procedure of Sarpogrelate HCl
KR101534606B1 (en) * 2011-11-08 2015-07-10 알보젠코리아 주식회사 Stabilized and extended release formation of sarpogrelate
CN102552165B (en) * 2012-01-05 2014-07-16 金陵药业股份有限公司 Sarpogrelate hydrochloride sustained release pellet and preparation method thereof
CN103284970A (en) * 2012-02-29 2013-09-11 锦华制药株式会社 Sarpogrelate hydrochloride sustained release preparation and preparation method thereof
KR20130135493A (en) * 2012-06-01 2013-12-11 씨제이제일제당 (주) Oral sustained-release matrix formulation comprising stabilized sarpogrelate hydrochloride and process for the preparation thereof
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions

Also Published As

Publication number Publication date
JP2019507795A (en) 2019-03-22
CN109069435A (en) 2018-12-21
KR20170106126A (en) 2017-09-20
CN109069435B (en) 2022-06-28
JP7366542B2 (en) 2023-10-23
WO2017155350A1 (en) 2017-09-14
KR101790286B1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
IL283134A (en) Alcohol-resistant drug formulations
IL257481B (en) Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof
HK1244704A1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
BR112017028140A2 (en) pharmaceutical formulations
HUP1700253A1 (en) Solid preparations for oral administration
HUE056922T2 (en) 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof
ZA201904241B (en) Novel compound and pharmacologically acceptable salt thereof
ZA202006570B (en) Pharmaceutical formulations
HK1255313A1 (en) Stabilized pharmaceutical composition containing pemetrexed or pharmaceutically acceptable salt thereof
IL290469A (en) Oral pharmaceutical composition
HK1214600A1 (en) Phosphorus-containing pyrido[2,3-d]pyrimidin-7-ones or their pharmaceutically acceptable salts, pharmaceutical compositions containing this compound and use thereof [23-d]-7-
HK1245646A1 (en) Pharmaceutical composition for oral administration
KR101790286B9 (en) -2-[2-3--3-]-3'- An oral pharmaceutical composition comprising -2-[2-3-carboxypropionyloxy-3-dimethylaminopropoxy]-3'-methoxybibenzyl or a pharmaceutically acceptable salt thereof
PT3632436T (en) Pharmaceutical composition comprising lenvatinib salts
HK1243351A1 (en) Pharmaceutical composition comprising pyridopyrimidine derivative or pharmaceutically acceptable salt thereof
PL3880171T3 (en) Ibuprofen-containing oral pharmaceutical formulation
SI3996688T1 (en) Pharmaceutical preparation
HRP20180819T1 (en) Pharmaceutical composition of sildenafil citrate in the form of a suspension for oral use
SG11202101547WA (en) Pharmaceutical composition for oral administration
SG11202009187YA (en) Pharmaceutical preparation
SG11202010792TA (en) Improved pharmaceutical formulations
HUP1600415A2 (en) Pimavanserin salts for the manufacture of pharmaceutical formulations
EP3409662A4 (en) Novel compound and pharmaceutically acceptable salt thereof
GB2561723B (en) A composition for oral administration
HK1250633A1 (en) Pharmaceutical composition of sildenafil citrate in the form of a suspension for oral use

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant
J202 Request for trial for correction [limitation]
J301 Trial decision

Free format text: TRIAL NUMBER: 2021105000129; TRIAL DECISION FOR CORRECTION REQUESTED 20211110

Effective date: 20220119